Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213

Background: There is no consensus on prognostic factors for advanced digestive neuroendocrine carcinoma (ADNEC). JCOG1213 was a phase III randomized trial that demonstrated equivalent overall survival (OS) between cisplatin plus etoposide and cisplatin plus irinotecan as first-line chemotherapy for...

Full description

Saved in:
Bibliographic Details
Main Authors: H. Hirano, K. Hirata, Y. Honma, C. Morizane, N. Machida, K. Kato, T. Okusaka, N. Boku, S. Sekine, N. Hiraoka, J. Mizusawa, Y. Sano, Y. Shibuya, M. Takahashi, N. Fujimori, M. Nomura, Y. Doki, M. Ueno, T. Yoshikawa, H. Takeuchi
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:ESMO Gastrointestinal Oncology
Subjects:
gastroenteropancreatic neuroendocrine carcinoma
prognostic factor
first-line chemotherapy
cisplatin
Online Access:http://www.sciencedirect.com/science/article/pii/S2949819825000470
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949819825000470

Similar Items